Search Results

You are looking at 1 - 8 of 8 items for :

Clear All
Open access

Athanasios D Anastasilakis, Marina Tsoli, Gregory Kaltsas and Polyzois Makras

effects have been reported in patients with LCH treated with bisphosphonates ( 60 ). Novel treatment approaches Denosumab, an antibody targeting RANKL, has been used as a treatment in osteoporosis and has recently been approved for diminishing the

Open access

Katherine Van Loon, Li Zhang, Jennifer Keiser, Cendy Carrasco, Katherine Glass, Maria-Teresa Ramirez, Sarah Bobiak, Eric K Nakakura, Alan P Venook, Manisha H Shah and Emily K Bergsland

form of bone-directed therapy: 50% received a form of radiation, 45% received a bisphosphonate, 18% underwent surgical resection, 13% received 131 I-MIBG, and 5% received denosumab. Moreover, 46% were treated with more than one treatment modality

Open access

Martine Cohen-Solal, Thomas Funck-Brentano and Pablo Ureña Torres

treatment of CKD stage 4–5D patients with osteoporosis, that is, low bone mass or fractures remained a challenge. A more recent drug offered new opportunities. Denosumab at the dose of 60 mg prescribed for the prevention of fracture in patients at high risk

Open access

Jennifer Walsh, Neil Gittoes, Peter Selby and the Society for Endocrinology Clinical Committee

Calcimimetics, denosumab, calcitonin Under specialist supervision Can be considered if poor response to other measures Parathyroidectomy Can be considered in acute presentation of primary hyperparathyroidism if severe hypercalcaemia and poor

Open access

Ann-Kristin Picke, Graeme Campbell, Nicola Napoli, Lorenz C Hofbauer and Martina Rauner

regarding non-vertebral fractures (reviewed in 176 ). Thus, even though bisphosphonate further suppress bone turnover, they may still be an effective therapy for patients with T2DM. Denosumab Denosumab is a monoclonal antibody targeted against RANKL

Open access

E Vignali, F Cetani, S Chiavistelli, A Meola, F Saponaro, R Centoni, L Cianferotti and C Marcocci

levels (e.g. Paget's disease) should be excluded. Finally, the use of medications which might affect PTH levels or calcium metabolism (estrogens, thiazide diuretics, lithium, bisphosphonates, denosumab and anticonvulsants) should also be ruled out (4

Open access

Maria Mizamtsidi, Constantinos Nastos, George Mastorakos, Roberto Dina, Ioannis Vassiliou, Maria Gazouli and Fausto Palazzo

normocalcemic pHPT ( 9 , 11 , 23 ), like malabsorption syndromes, hypercalciuria and certain medications such as bisphosphonates, denosumab and loop diuretics. The presence of pHPT in children and young adults may be associated with the hereditary

Open access

K Amrein, A Papinutti, E Mathew, G Vila and D Parekh

denosumab and parenteral bisphosphonates are necessary in the near future. Effects of enterally administered vitamin D supplementation Van den Berghe et al . ( 1 ) tried to demonstrate that in critically ill patients an intravenous supplementation